DDrare: Database of Drug Development for Rare Diseases

Dasatinib (DrugBank: Dasatinib)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
85	特発性間質性肺炎	1

51. 全身性強皮症　［臨床試験数：466，薬物数：536（DrugBank：142），標的遺伝子数：110，標的パスウェイ数：210］

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 466 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00764309 (ClinicalTrials.gov)	January 2009	1/10/2008	Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis	An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis	Scleroderma	Drug: dasatinib	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	47	Phase 1;Phase 2	United States

85. 特発性間質性肺炎　［臨床試験数：514，薬物数：377（DrugBank：108），標的遺伝子数：97，標的パスウェイ数：204］

Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 514 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02874989 (ClinicalTrials.gov)	December 16, 2016	17/8/2016	Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial	Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Drug: Dasatinib + Quercetin;Drug: Placebo	Wake Forest University Health Sciences	Mayo Clinic;The University of Texas Health Science Center at San Antonio	Completed	50 Years	N/A	All	26	Phase 1	United States